Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Melissa G Jean"'
Autor:
Hui Zheng, Eirini Pectasides, Mohamed Uduman, Charles S Fuchs, James M Cleary, Adam J Bass, Jérémy Augustin, Leonie K de Klerk, Anuj K Patel, Sarah Derks, Nihal Raman, Fahire G Akarca, Nadine J McCleary, Douglas A Rubinson, Jeffrey W Clark, Bridget Fitzpatrick, Lauren K Brais, Megan E Cavanaugh, Amanda J Rode, Melissa G Jean, Patrick H Lizotte, Matthew J Nazzaro, Peter C Enzinger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/88b5dffda1124385a9d172a7073bce20
Autor:
Eirini Pectasides, Sarah Derks, Charles S. Fuchs, Megan E. Cavanaugh, Peter C. Enzinger, Anuj K. Patel, Amanda J. Rode, Douglas A. Rubinson, Adam J. Bass, Bridget Fitzpatrick, Lauren K. Brais, Nadine Jackson McCleary, Mariano Severgnini, Patrick H. Lizotte, Fahire G Akarca, Jeffrey W. Clark, Leonie K. de Klerk, Melissa G Jean, Matthew Nazzaro, Jeremy Augustin, Mohamed Uduman, James M. Cleary, Hui Zheng, Nihal Raman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
BackgroundImmune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed.